
Verona Pharma appoints chief financial officer
pharmafile | October 8, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | roy biresh, verona pharma
London-based drug development firm Verona Pharma has hired Biresh Roy as its chief financial officer and member of the board of directors.
Roy who replaces Richard Bungay in his role – which was part-time and a non-board position, has much pharma experience and a strong track record in executing and financing merger and acquisition deals according to the firm.
Roy is a current director of both Ebury Bridge Management and Ebury Restructuring Partners and during the past five years was a director of Future Metals (Europe).
In December 2012 Biresh founded Ebury Capital and Growth Solutions, and between 2004 and 2011 was an adviser to several venture capital and private equity firms. During this time he also acted as chief financial officer for several companies.
Dr Jan-Anders Karlsson, chief executive of Verona Pharma, says: “Having successfully raised significant capital earlier this year, we look forward to having Biresh on our team. His experience will be invaluable as we build the Company and seek to develop the full potential of RPL554 in respiratory disease to create significant shareholder value.”
Roy adds: “I am very pleased to be joining my new colleagues at Verona Pharma. I am confident that together we will be able to create significant value for our investors, and ultimately benefits for patients, by advancing novel medicines such as RPL554.”
Related Content

Verona Pharma to share phase 3 COPD trial data at ATS 2024
Verona Pharma has announced that it will share eight posters at the American Thoracic Society …

Verona Pharma submits FDA New Drug Application for COPD treatment
UK-based Verona Pharma has announced that it has submitted a New Drug Application (NDA) to …

Verona’s shares drop 34% on Phase 2 failure of nebulised ensifentrine in COPD
Verona Pharma has seen its shares crater following the Phase 2 failure of its nebulised …






